Use: Labeled indications
- ARICEPT is indicated for the treatment of dementia of the Alzheimer’s type.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ARICEPT is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease (1)
Contraindications
4 CONTRAINDICATIONS ARICEPT is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. Known hypersensitivity to donepezil hydrochloride or to piperidine derivatives (4)
US FDA labelDosing: Adult
- Mild to Moderate Alzheimer’s Disease: 5 mg to 10 mg once daily (2.1)
- Moderate to Severe Alzheimer’s Disease: 10 mg to 23 mg once daily (2.2)
2.1 Dosing in Mild to Moderate Alzheimer’s Disease
2.1 Dosing in Mild to Moderate Alzheimer’s Disease The recommended starting dosage of ARICEPT is 5 mg administered once per day in the evening, just prior to retiring. The maximum recommended dosage of ARICEPT in patients with mild to moderate Alzheimer’s disease is 10 mg per day. A dose of 10 mg should not be administered until patients have been on a daily dose of 5 mg for 4 to 6 weeks.
2.2 Dosing in Moderate to Severe Alzheimer’s Disease
2.2 Dosing in Moderate to Severe Alzheimer’s Disease The recommended starting dosage of ARICEPT is 5 mg administered once per day in the evening, just prior to retiring. The maximum recommended dosage of ARICEPT in patients with moderate to severe Alzheimer’s disease is 23 mg per day. A dose of 10 mg should not be administered until patients have been on a daily dose of 5 mg for 4 to 6 weeks.
A dose of 23 mg per day should not be administered until patients have been on a daily dose of 10 mg for at least 3 months.
2.3 Administration Information
2.3 Administration Information ARICEPT should be taken in the evening, just prior to retiring. ARICEPT can be taken with or without food. The ARICEPT 23 mg tablet should not be split, crushed, or chewed. Allow ARICEPT ODT to dissolve on the tongue and follow with water.
Dosing: Altered kidney function
Renal Disease In a study of 11 patients with moderate to severe renal impairment (Cl C < 18 mL/min/1.73 m²) the clearance of ARICEPT did not differ from 11 age- and sex-matched healthy subjects.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8. 5 Geriatric Use Alzheimer’s disease is a disorder occurring primarily in individuals over 55 years of age. The mean age of patients enrolled in the clinical studies with ARICEPT was 73 years; 80% of these patients were between 65 and 84 years old, and 49% of patients were at or above the age of 75. The efficacy and safety data presented in the clinical trials section were obtained from these patients. There were no clinically significant differences in most adverse reactions reported by patient groups ≥ 65 years old and < 65 years old.
Administration
2.3 Administration Information ARICEPT should be taken in the evening, just prior to retiring. ARICEPT can be taken with or without food. The ARICEPT 23 mg tablet should not be split, crushed, or chewed. Allow ARICEPT ODT to dissolve on the tongue and follow with water.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 5 mg, 10 mg, 23 mg
- Orodispersible tablet: 5 mg, 10 mg
- Orally disintegrating strips: 5 mg, 10 mg
- Orally disintegrating tablet: 10 mg
Registered products in the Philippines
47 products registered with the Food and Drug Administration (FDA) Philippines list Donepezil as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products47
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlnepezilDonepezil Hydrochloride | 10 mg Film-Coated TabletAlu/Amber PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Metro Pharma Philippines, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-6312-01 | Jul 31, 2027 | |
AlzancerDonepezil hydrochloride | 10 mg Orodispersible TabletAlu/PVC/OPA/AL/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Nobel Ilac Sanayii Ve Ticaret A.S.Turkey | MULTICARE PHARMACEUTICALS PHILS. INC.Importer: Ambicare Pharmaceuticals Inc. | DRP-8590 | Dec 18, 2029 | |
AlzancerDonepezil hydrochloride | 5 mg Orodispersible TabletAlu/PVC/OPA/AL/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Nobel Ilac Sanayii Ve Ticaret A.S.Turkey | MULTICARE PHARMACEUTICALS PHILS. INC.Importer: Ambicare Pharmaceuticals Inc. | DRP-8589 | Dec 18, 2029 | |
AlzimeDonepezil Hydrochloride | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Berlin Pharmaceutical Industry Co. Ltd.Thailand | Metro Drug Inc.Importer: Paradigm Pharma (Philippines) Corporation | DR-XY48008 | May 10, 2027 | |
AriceptDonepezil hydrochloride | 23 mg Film-Coated TabletBox of 1 Aluminum Foil wrapper containing 4 PCTFE/PVC Blister Pack x 7's | RxVAT-exempt | Eisai Co., Ltd. (Kawashima Plant)Japan | Zuellig Pharma CorporationImporter: HI-Eisai Pharmaceutical Inc. | DR-XY42383 | Aug 29, 2028 | |
Aricept EvessDonepezil Hydrochloride | 10 mg Orodispersible TabletAlu/PVC Blister Pack in Aluminum Pouch x 14's (Box of 28's) | RxVAT-exempt | Bushu Pharmaceuticals Ltd. (Misato Factory)Japan | Zuellig Pharma CorporationImporter: HI-EISAI PHARMACEUTICAL INC. | DR-XY35548 | Mar 5, 2029 | |
Aricept EvessDonepezil Hydrochloride | 5 mg Orodispersible TabletAlu/PVC Blister Pack in Aluminum Pouch x 14's (Box of 28's) | RxVAT-exempt | Bushu Pharmaceuticals Ltd. (Misato Factory)Japan | Zuellig Pharma CorporationImporter: HI-EISAI PHARMACEUTICAL INC. | DR-XY35549 | Mar 5, 2029 | |
Arizil 10Donepezil Hydrochloride | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Sun Pharmaceutical Industries Ltd.India | Sun Pharma Philippines, Inc. | DRP-8227 | Apr 26, 2028 | |
Arizil 5Donepezil Hydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 30's | RxVAT-exempt | Sun Pharmaceutical Industries Ltd.India | Sun Pharma Philippines, Inc. | DRP-8228 | Apr 26, 2028 | |
AzimentiaDonepezil hydrochloride (as monohydrate) | 10 mg Orodispersible TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | KRKA, D.D., Novo MestoSlovenia | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DRP-14695 | Nov 29, 2028 | |
AzimentiaDonepezil Hydrochloride | 5 mg Orodispersible TabletAlu/Alu Blister Pack of 7's | RxVAT-exempt | KRKA, D.D., Novo MestoSlovenia | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DRP-14719 | Dec 4, 2028 | |
Done-10Donepezil Hydrochloride | 10 mg Film-Coated TabletAlu/Amber PVDC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-6312 | Jul 31, 2027 | |
DonepedinDonepezil hydrochloride | 10 mg Film-Coated TabletAlu/PVC/PVDC blister pack x 10's (Box of 30's) | RxVAT-exempt | Whan In Pharm. Co., Ltd.Republic of Korea | Medchoice Cns Pharma CorporationImporter: JLT PHARMA INC. | DRP-8758-01 | Mar 2, 2037 | |
DonepedinDonepezil hydrochloride | 5 mg Film-Coated TabletAlu/PVC/PVDC blister pack x 10's (Box of 30's) | RxVAT-exempt | Whan In Pharm. Co., Ltd.Republic of Korea | Medchoice Cns Pharma CorporationImporter: JLT PHARMA INC. | DRP-8757-01 | Mar 7, 2037 | |
Donepesaph-10Donepezil Hydrochloride | 10 mg Film-Coated TabletAlu/PVC Blister Pack and 10’s (Box of 30’s, and 100’s) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-19009 | Oct 19, 2031 | |
Donepesaph-23Donepezil Hydrochloride | 23 mg Film-Coated TabletAlu/PVC Blister Pack of 7’s (Box of 28’s) and 10’s (Box of 30’s, and 100’s) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-19008 | Oct 19, 2031 | |
Donepesaph-5Donepezil Hydrochloride | 5 mg Film-Coated TabletAlu/PVC Blister Pack and 10’s (Box of 30’s, and 100’s) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-19010 | Oct 19, 2031 | |
Donepesaph-GE23Donepezil Hydrochloride | 23 mg Film-Coated TabletAlu/PVC Blister Pack of 7’s (Box of 28’s) and 10’s (Box of 30’s, and 100’s) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-19007 | Oct 19, 2031 | |
Donephil-10Donepezil | 10 mg Film Coated TabletAlu-Alu Blister Pack x 10's | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co, Ltd.China | Amb Hk Enterprises Inc. | DRP-19011 | Oct 19, 2031 | |
DoneprizilDonepezil hydrochloride | 10 mg Orally Disintegrating TabletAlu-PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14633 | Nov 8, 2028 | |
DonzilDonepezil hydrochloride | 5 mg Orodispersible TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-17259 | Nov 4, 2030 | |
DopezilDonepezil hydrochloride | 10 mg Film-Coated TabletPVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Jubilant Generics LimitedIndia | UNILAB, Inc. | DR-XY37546 | Mar 15, 2031 | |
DopezilDonepezil hydrochloride | 5 mg Film-Coated TabletPVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Jubilant Generics LimitedIndia | UNILAB, Inc. | DR-XY37545 | Mar 12, 2031 | |
Dosena-10Donepezil hydrochloride | 10 mg Orodispersible TabletAlu/PVC/OPA/AL/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Nobel Ilac Sanayii Ve Ticaret A.S.Turkey | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-8590-01 | Dec 18, 2029 | |
Dosena-5Donepezil hydrochloride | 5 mg Orodispersible TabletAlu/PVC/OPA/AL/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Nobel Ilac Sanayii Ve Ticaret A.S.Turkey | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-8589-01 | Dec 18, 2029 | |
Getbak 10Donepezil hydrochloride | 10mg Film-Coated TabletAlu/Clear PVC/PE/PVDC Blister Pack x 14's | RxVAT-exempt | Aurobindo Pharma LimitedIndia | AAA Pharma, Inc. | DR-XY49482 | Sep 2, 2030 | |
Getbak 5Donepezil hydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC/PE/PVDC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Aurobindo Pharma LimitedIndia | AAA Pharma, Inc. | DR-XY49483 | Sep 2, 2030 | |
NepanizilDonepezil hydrochloride | 10mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 14's (Box of 28's, 56's, 84's and 98's) | RxVAT-exempt | Medicair Bioscience Laboratories S.A.Greece | Despina Pharma Inc. | DRP-16913 | Aug 27, 2030 | |
NepanizilDonepezil hydrochloride | 5mg Film-Coated TabletAlu-PVDC Blister Pack x 14's (Box of 28's, 56's, 84's and 98's) | RxVAT-exempt | Medicair Bioscience Laboratories S.A.Greece | Despina Pharma Inc. | DRP-16914 | Aug 27, 2030 | |
NoneDonepezil hydrochloride | 10 mg Film-Coated TabletAlu/PVC/PVDC blister pack x 10's (Box of 30's) | RxVAT-exempt | Whan In Pharm. Co., LtdRepublic of Korea | Ritemed Phils., Inc.Importer: Jlt Pharma Inc. | DRP-8758 | Mar 11, 2030 | |
NoneDonepezil hydrochloride | 5 mg Film-Coated TabletAlu/PVC/PVDC blister pack x 10's (Box of 30's) | RxVAT-exempt | Whan In Pharm. Co., Ltd.Republic of Korea | Ritemed Phils., Inc.Importer: JLT Pharma, Inc. | DRP-8757 | Mar 11, 2030 | |
Onzepil 5Donepezil hydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15822 | Sep 18, 2029 | |
ServonexDonepezil Hydrochloride | 10 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 50's); Alu/Clear PVC/PVDC Blister Pack x 1's (Box of 1's and x 5's as Physician's Sample) | RxVAT-exempt | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DR-XY43385 | May 9, 2029 | |
ServonexDonepezil (as Hydrochloride) | 5 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 30's and 50's); Alu/Clear PVC/PVDC Blister Pack x 1's (Box of 1's) as Physician's Sample; Alu/Clear PVC/PVDC Blister Pack x 5's as Physician's Sample | RxVAT-exempt | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY44130 | Feb 2, 2027 | |
Torpezil 10Donepezil Hydrochloride | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DRP-3263 | Sep 24, 2030 | |
Torpezil 5Donepezil Hydrochloride | 5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines Inc. | DRP-3262 | Sep 24, 2030 | |
Vexdim 10Donepezil hydrochloride | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | West-Coast Pharmaceuticals Works Ltd.India | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY47626 | Dec 22, 2031 | |
Vexdim 10 ODTDonepezil hydrochloride | 10 mg Orally Disintegrating TabletAlu-PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | VE Pharma Inc.Importer: Ambica International Corporation | DRP-14633-01 | Nov 8, 2028 | |
Vexdim 5Donepezil hydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY47625 | Dec 22, 2031 | |
Vexdim 5Donepezil hydrochloride | 5 mg Orodispersible TabletAlu/PVC/OPA/AL/PVC Blister Pack x 7's (Box of 28’s) | RxVAT-exempt | Nobel Ilac Sanayii Ve Ticaret A.S.Turkey | VE Pharma, Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-8589-02 | Dec 18, 2029 | |
Zypezil 10Donepezil Hydrochloride | 10 mg Film-Coated TabletWhite opaque PVC/PVDC/Alu Blister Pack x 10's Box of 30's; White opaque PVC/PVDC/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7600 | Oct 3, 2029 | |
Zypezil 5Donepezil Hydrochloride | 5 mg Film-Coated TabletWhite opaque PVC/PVDC/Alu Blister Pack x 10's Box of 100's; White opaque PVC/PVDC/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7573 | Oct 3, 2029 | |
Zypezil Od 10Donepezil hydrochloride | 10 mg Orodispersible TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu/Alu Blister Pack x 10's (Box of 10's) -As physician sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-13979 | May 30, 2028 | |
Zypezil OD 5Donepezil Hydrochloride | 5 mg Orodispersible TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu/Alu Blister Pack x 10's (Box of 10's) As physician sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-14000 | Jun 2, 2028 | |
Zypezil ODT 10Donepezil Hydrochloride | 10 mg Orodispersible TabletAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DR-XY46911 | Jun 16, 2030 | |
(no brand name)Donepezil Hydrochloride | 10mg Orally Disintegrating StripsTriple laminated foil (Polyethylene tetraphthalate/Aluminum foil/Polyethylene) in sachet x 1's strip (Box of 10's) | RxVAT-exempt | Zim Laboratories LimitedIndia | I.E. Medica, Inc. | DR-XY49757 | Jul 2, 2031 | |
(no brand name)Donepezil Hydrochloride | 5mg Orally Disintegrating StripsTriple laminated foil (Polyethylene tetraphthalate/Aluminum foil/Polyethylene) sachet x 1's strip (Box of 10's) | RxVAT-exempt | Zim Laboratories LimitedIndia | I.E. Medica, Inc. | DR-XY49756 | Jul 2, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS ARICEPT is supplied as film-coated, round tablets containing 5 mg, 10 mg, or 23 mg of donepezil hydrochloride. The 5 mg tablets are white. The strength, in mg (5), is debossed on one side and ARICEPT is debossed on the other side. The 10 mg tablets are yellow. The strength, in mg (10), is debossed on one side and ARICEPT is debossed on the other side.
The 23 mg tablets are reddish. The strength, in mg (23), is debossed on one side, and ARICEPT is debossed on the other side. ARICEPT ODT is supplied as round tablets containing either 5 mg or 10 mg of donepezil hydrochloride. The 5 mg orally disintegrating tablets are white. The strength, in mg (5), is debossed on one side and ARICEPT is debossed on the other side.
The 10 mg orally disintegrating tablets are yellow. The strength, in mg (10), is debossed on one side and ARICEPT is debossed on the other side. Tablets: 5 mg, 10 mg, and 23 mg (3) Orally Disintegrating Tablets (ODT): 5 mg and 10 mg (3)
Warnings/Precautions
- Cholinesterase inhibitors are likely to exaggerate succinylcholine-type muscle relaxation during anesthesia (5.1)
- Cholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block (5.2)
- ARICEPT can cause vomiting. Patients should be observed closely at initiation of treatment and after dose increases (5.3)
- Patients should be monitored closely for symptoms of active or occult gastrointestinal (GI) bleeding, especially those at increased risk for developing ulcers (5.4)
- The use of ARICEPT in a dose of 23 mg once daily is associated with weight loss (5.5)
- Cholinomimetics may cause bladder outflow obstructions (5.6)
- Cholinomimetics are believed to have some potential to cause generalized convulsions (5.7)
- Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease (5.8)
5.1 Anesthesia
5.1 Anesthesia ARICEPT, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.
5.2 Cardiovascular Conditions
5.2 Cardiovascular Conditions Because of their pharmacological action, cholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes. This effect may manifest as bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of ARICEPT.
5.3 Nausea and Vomiting
5.3 Nausea and Vomiting ARICEPT, as a predictable consequence of its pharmacological properties, has been shown to produce diarrhea, nausea, and vomiting. These effects, when they occur, appear more frequently with the 10 mg/day dose than with the 5 mg/day dose, and more frequently with the 23 mg dose than with the 10 mg dose.
Specifically, in a controlled trial that compared a dose of 23 mg/day to 10 mg/day in patients who had been treated with donepezil 10 mg/day for at least three months, the incidence of nausea in the 23 mg group was markedly greater than in the patients who continued on 10 mg/day (11.8% vs. 3.4%, respectively), and the incidence of vomiting in the 23 mg group was markedly greater than in the 10 mg group (9.2% vs. 2.5%, respectively). The percent of patients who discontinued treatment due to vomiting in the 23 mg group was markedly higher than in the 10 mg group (2.9% vs. 0.4%, respectively).
Although in most cases, these effects have been transient, sometimes lasting one to three weeks, and have resolved during continued use of ARICEPT, patients should be observed closely at the initiation of treatment and after dose increases.
5.4 Peptic Ulcer Disease and GI Bleeding
5.4 Peptic Ulcer Disease and GI Bleeding Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).
Clinical studies of ARICEPT in a dose of 5 mg/day to 10 mg/day have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Results of a controlled clinical study with 23 mg/day showed an increase, relative to 10 mg/day, in the incidence of peptic ulcer disease (0.4% vs. 0.2%) and gastrointestinal bleeding from any site (1.1% vs. 0.6%).
5.5 Weight Loss
5.5 Weight Loss Weight loss was reported as an adverse reaction in 4.7% of patients assigned to ARICEPT in a dose of 23 mg/day compared to 2.5% of patients assigned to 10 mg/day. Compared to their baseline weights, 8.4% of patients taking 23 mg/day were found to have a weight decrease of ≥ 7% by the end of the study, while 4.9% of patients taking 10 mg/day were found to have weight loss of ≥ 7% at the end of the study.
5.6 Genitourinary Conditions
5.6 Genitourinary Conditions Although not observed in clinical trials of ARICEPT, cholinomimetics may cause bladder outflow obstruction.
5.7 Neurological Conditions
5.7 Neurological Conditions: Seizures Cholinomimetics are believed to have some potential to cause generalized convulsions. However, seizure activity also may be a manifestation of Alzheimer’s disease.
5.8 Pulmonary Conditions
5.8 Pulmonary Conditions Because of their cholinomimetic actions, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.
Drug interactions
- Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications (7.1)
- A synergistic effect may be expected with concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists (7.2)
7.1 Use with Anticholinergics
7.1 Use with Anticholinergics Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
7.2 Use with Cholinomimetics and Other
7.2 Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation.
Examination of the effect of CYP2D6 genotype in Alzheimer’s patients showed differences in clearance values among CYP2D6 genotype subgroups.
Drug Interactions Effect of ARICEPT on the Metabolism of Other Drugs No in vivo clinical trials have investigated the effect of ARICEPT on the clearance of drugs metabolized by CYP 3A4 (e.g., cisapride, terfenadine) or by CYP 2D6 (e.g., imipramine).
Based on in vitro studies, donepezil shows little or no evidence of direct inhibition of CYP2B6, CYP2C8, and CYP2C19 at clinically relevant concentrations.
Effect of Other Drugs on the Metabolism of ARICEPT Ketoconazole and quinidine, strong inhibitors of CYP450 3A and 2D6, respectively, inhibit donepezil metabolism in vitro .
Population pharmacokinetic analysis showed that in the presence of concomitant CYP2D6 inhibitors donepezil AUC was increased by approximately 17% to 20% in Alzheimer’s disease patients taking ARICEPT 10 and 23 mg.
This represented an average effect of weak, moderate, and strong CYP2D6 inhibitors.
Inducers of CYP 3A (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of ARICEPT.
Adverse reactions
- The following serious adverse reactions are described below and elsewhere in the labeling: Cardiovascular Conditions [see Warnings and Precautions (5.2)] Nausea and Vomiting [see Warnings and Precautions (5.3)] Peptic Ulcer Disease and GI Bleeding [see Warnings and Precautions (5.4)] Weight Loss [see Warnings and Precautions (5.5)] Genitourinary Conditions [see Warnings and Precautions (5.6)] Neurological Conditions: Seizures [see Warnings and Precautions (5.7)] Pulmonary Conditions [see Warnings and Precautions (5.8)] Most common adverse reactions in clinical studies of ARICEPT are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 (fax 1-201-746-3207) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ARICEPT has been administered to over 1,700 individuals during clinical trials worldwide.
Approximately 1200 of these patients have been treated for at least 3 months and more than 1,000 patients have been treated for at least 6 months. Controlled and uncontrolled trials in the United States included approximately 900 patients. In regards to the highest dose of 10 mg/day, this population includes 650 patients treated for 3 months, 475 patients treated for 6 months, and 116 patients treated for over 1 year.
The range of patient exposure is from 1 to 1,214 days. Mild to Moderate Alzheimer ’ s Disease Adverse Reactions Leading to Discontinuation The rates of discontinuation from controlled clinical trials of ARICEPT due to adverse reactions for the ARICEPT 5 mg/day treatment groups were comparable to those of placebo treatment groups at approximately 5%.
The rate of discontinuation of patients who received 7-day escalations from 5 mg/day to 10 mg/day was higher at 13%. The most common adverse reactions leading to discontinuation, defined as those occurring in at least 2% of patients and at twice or more the incidence seen in placebo patients, are shown in Table 1. Table 1.
Most Common Adverse Reactions Leading to Discontinuation in Patients with Mild to Moderate Alzheimer’s Disease Adverse Reaction Placebo (n=355) % 5 mg/day ARICEPT (n=350) % 10 mg/day ARICEPT (n=315) % Nausea 1 1 3 Diarrhea 0 <1 3 Vomiting <1 <1 2 Most Common Adverse Reactions The most common adverse reactions, defined as those occurring at a frequency of at least 5% in patients receiving 10 mg/day and twice the placebo rate, are largely predicted by ARICEPT’s cholinomimetic effects. These include nausea, diarrhea, insomnia, vomiting, muscle cramp, fatigue, and anorexia.
These adverse reactions were often transient, resolving during continued ARICEPT treatment without the need for dose modification. There is evidence to suggest that the frequency of these common adverse reactions may be affected by the rate of titration. An open-label study was conducted with 269 patients who received placebo in the 15- and 30-week studies.
These patients were titrated to a dose of 10 mg/day over a 6-week period. The rates of common adverse reactions were lower than those seen in patients titrated to 10 mg/day over one week in the controlled clinical trials and were comparable to those seen in patients on 5 mg/day. See Table 2 for a comparison of the most common adverse reactions following one and six week titration regimens.
Table 2. Comparison of Rates of Adverse Reactions in Mild to M oderate Patients Titrated to 10 mg/day over 1 and 6 Weeks No titration One week titration Six week titration Adverse Reaction Placebo (n=315) % 5 mg/day (n=311) % 10 mg/day (n=315) % 10 mg/day (n=269) % Nausea 6 5 19 6 Diarrhea 5 8 15 9 Insomnia 6 6 14 6 Fatigue 3 4 8 3 Vomiting 3 3 8 5 Muscle cramps 2 6 8 3 Anorexia 2 3 7 3 Table 3 lists adverse reactions that occurred in at least 2% of patients in pooled placebo-controlled trials who received either ARICEPT 5 mg or 10 mg and for which the rate of occurrence was greater for patients treated with ARICEPT than with placebo.
In general, adverse reactions occurred more frequently in female patients and with advancing age. Table 3. Adverse Reactions in Pooled Placebo- Controlled Clinical Trials in Mild to Moderate Alzheimer’s Disease Adverse Reaction Placebo (n=355) % ARICEPT (n=747) % Percent of Pa tients with any Adverse Reaction 72 74 Nausea 6 11 Diarrhea 5 10 Headache 9 10 Insomnia 6 9 Pain, various locations 8 9 Dizziness 6 8 Accident 6 7 Muscle Cramps 2 6 Fatigue 3 5 Vomiting 3 5 Anorexia 2 4 Ecchymosis 3 4 Abnormal Dreams 0 3 Depression <1 3 Weight Loss 1 3 Arthritis 1 2 Frequent Urination 1 2 Somnolence <1 2 Syncope 1 2 Severe Alzheimer’s Disease (ARICEPT 5 mg/day and 10 mg/day) ARICEPT has been administered to over 600 patients with severe Alzheimer’s disease during clinical trials of at least 6 months duration, including three double-blind, placebo-controlled trials, two of which had an open label extension.
Adverse Reactions Leading to Discontinuation The rates of discontinuation from controlled clinical trials of ARICEPT due to adverse reactions for the ARICEPT patients were approximately 12% compared to 7% for placebo patients. The most common adverse reactions leading to discontinuation, defined as those occurring in at least 2% of ARICEPT patients and at twice or more the incidence seen in placebo, were anorexia (2% vs. 1% placebo), nausea (2% vs. <1% placebo), diarrhea (2% vs. 0% placebo), and urinary tract infection (2% vs. 1% placebo).
Most Common Adverse Reactions The most common adverse reactions, defined as those occurring at a frequency of at least 5% in patients receiving ARICEPT and at twice or more the placebo rate, are largely predicted by ARICEPT’s cholinomimetic effects. These include diarrhea, anorexia, vomiting, nausea, and ecchymosis. These adverse reactions were often transient, resolving during continued ARICEPT treatment without the need for dose modification.
Table 4 lists adverse reactions that occurred in at least 2% of patients in pooled placebo-controlled trials who received ARICEPT 5 mg or 10 mg and for which the rate of occurrence was greater for patients treated with ARICEPT than with placebo. Table 4. Adverse Reactions in Pooled Controlled Clinical Trials in Severe Alzheimer’s Disease Body System/Adverse Reaction Placebo (n=392) % ARICEPT (n=501) % Percent of Patients with any Adverse Reaction 73 81 Accident 12 13 Infection 9 11 Diarrhea 4 10 Anorexia 4 8 Vomiting 4 8 Nausea 2 6 Insomnia 4 5 Ecchymosis 2 5 Headache 3 4 Hypertension 2 3 Pain 2 3 Back Pain 2 3 Eczema 2 3 Hallucinations 1 3 Hostility 2 3 Increase in Creatine Phosphokinase 1 3 Nervousness 2 3 Fever 1 2 Chest Pain <1 2 Confusion 1 2 Dehydration 1 2 Depression 1 2 Dizziness 1 2 Emotional Lability 1 2 Hemorrhage 1 2 Hyperlipemia <1 2 Personality Disorder 1 2 Somnolence 1 2 Syncope 1 2 Urinary Incontinence 1 2 Moderate to Severe Alzheimer’s Disease (ARICEPT 23 mg/day) ARICEPT 23 mg/day has been administered to over 1300 individuals globally in clinical trials.
Approximately 1050 of these patients have been treated for at least three months and more than 950 patients have been treated for at least six months. The range of patient exposure was from 1 to over 500 days. Adverse Reactions Leading to Discontinuation The rate of discontinuation from a controlled clinical trial of ARICEPT 23 mg/day due to adverse reactions was higher (19%) than for the 10 mg/day treatment group (8%).
The most common adverse reactions leading to discontinuation, defined as those occurring in at least 1% of patients and greater than those occurring with 10 mg/day are shown in Table 5. Table 5. Most Common Adverse Reactions Leading to Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease Adverse Reaction 23 mg/day ARICEPT (n=963) % 10 mg/day ARICEPT (n=471) % Vomiting 3 0 Diarrhea 2 0 Nausea 2 0 Dizziness 1 0 The majority of discontinuations due to adverse reactions in the 23 mg group occurred during the first month of treatment.
Most Common Adverse Reactions with ARICEPT 23 mg /day The most common adverse reactions, defined as those occurring at a frequency of at least 5%, include nausea, diarrhea, vomiting, and anorexia. Table 6 lists adverse reactions that occurred in at least 2% of patients who received 23 mg/day of ARICEPT and at a higher frequency than those receiving 10 mg/day of ARICEPT in a controlled clinical trial that compared the two doses.
In this study, there were no important differences in the type of adverse reactions in patients taking ARICEPT with or without memantine. Table 6. Adverse Reactions in a Controlled Clinical Trial in Moderate to Severe Alzheimer’s Disease Adverse Reaction 23 mg/day ARICEPT (n=963) % 10 mg/day ARICEPT (n=471) % Percent of Patie nts with any Adverse Reaction 74 64 Nausea 12 3 Vomiting 9 3 Diarrhea 8 5 Anorexia 5 2 Dizziness 5 3 Weight Loss 5 3 Headache 4 3 Insomnia 3 2 Urinary Incontinence 3 1 Asthenia 2 1 Contusion 2 0 Fatigue 2 1 Somnolence 2 1
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ARICEPT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Abdominal pain, agitation, aggression, cholecystitis, confusion, convulsions, hallucinations, heart block (all types), hemolytic anemia, hepatitis, hyponatremia, neuroleptic malignant syndrome, pancreatitis, rash, rhabdomyolysis, QTc prolongation, and torsade de pointes.
Adverse reaction frequency tables (US label) US FDA label
| Table 1. Most Common Adverse Reactions Leading to Discontinuation in Patients with Mild to Moderate Alzheimer’s Disease | |||
| Adverse Reaction | Placebo (n=355) % | 5 mg/day ARICEPT (n=350) % | 10 mg/day ARICEPT (n=315) % |
| Nausea | 1 | 1 | 3 |
| Diarrhea | 0 | <1 | 3 |
| Vomiting | <1 | <1 | 2 |
| Table 2. Comparison of Rates of Adverse Reactions in Mild to Moderate Patients Titrated to 10 mg/day over 1 and 6 Weeks | ||||
| No titration | One week titration | Six week titration | ||
| Adverse Reaction | Placebo (n=315) % | 5 mg/day (n=311) % | 10 mg/day (n=315) % | 10 mg/day (n=269) % |
| Nausea | 6 | 5 | 19 | 6 |
| Diarrhea | 5 | 8 | 15 | 9 |
| Insomnia | 6 | 6 | 14 | 6 |
| Fatigue | 3 | 4 | 8 | 3 |
| Vomiting | 3 | 3 | 8 | 5 |
| Muscle cramps | 2 | 6 | 8 | 3 |
| Anorexia | 2 | 3 | 7 | 3 |
| Table 3. Adverse Reactions in Pooled Placebo-Controlled Clinical Trials in Mild to Moderate Alzheimer’s Disease | ||
| Adverse Reaction | Placebo (n=355) % | ARICEPT (n=747) % |
| Percent of Patients with any Adverse Reaction | 72 | 74 |
| Nausea | 6 | 11 |
| Diarrhea | 5 | 10 |
| Headache | 9 | 10 |
| Insomnia | 6 | 9 |
| Pain, various locations | 8 | 9 |
| Dizziness | 6 | 8 |
| Accident | 6 | 7 |
| Muscle Cramps | 2 | 6 |
| Fatigue | 3 | 5 |
| Vomiting | 3 | 5 |
| Anorexia | 2 | 4 |
| Ecchymosis | 3 | 4 |
| Abnormal Dreams | 0 | 3 |
| Depression | <1 | 3 |
| Weight Loss | 1 | 3 |
| Arthritis | 1 | 2 |
| Frequent Urination | 1 | 2 |
| Somnolence | <1 | 2 |
| Syncope | 1 | 2 |
| Table 4. Adverse Reactions in Pooled Controlled Clinical Trials in Severe Alzheimer’s Disease | ||
| Body System/Adverse Reaction | Placebo (n=392) % | ARICEPT (n=501) % |
| Percent of Patients with any Adverse Reaction | 73 | 81 |
| Accident | 12 | 13 |
| Infection | 9 | 11 |
| Diarrhea | 4 | 10 |
| Anorexia | 4 | 8 |
| Vomiting | 4 | 8 |
| Nausea | 2 | 6 |
| Insomnia | 4 | 5 |
| Ecchymosis | 2 | 5 |
| Headache | 3 | 4 |
| Hypertension | 2 | 3 |
| Pain | 2 | 3 |
| Back Pain | 2 | 3 |
| Eczema | 2 | 3 |
| Hallucinations | 1 | 3 |
| Hostility | 2 | 3 |
| Increase in Creatine Phosphokinase | 1 | 3 |
| Nervousness | 2 | 3 |
| Fever | 1 | 2 |
| Chest Pain | <1 | 2 |
| Confusion | 1 | 2 |
| Dehydration | 1 | 2 |
| Depression | 1 | 2 |
| Dizziness | 1 | 2 |
| Emotional Lability | 1 | 2 |
| Hemorrhage | 1 | 2 |
| Hyperlipemia | <1 | 2 |
| Personality Disorder | 1 | 2 |
| Somnolence | 1 | 2 |
| Syncope | 1 | 2 |
| Urinary Incontinence | 1 | 2 |
| Table 5. Most Common Adverse Reactions Leading to Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease | ||
| Adverse Reaction | 23 mg/day ARICEPT (n=963) % | 10 mg/day ARICEPT (n=471) % |
| Vomiting | 3 | 0 |
| Diarrhea | 2 | 0 |
| Nausea | 2 | 0 |
| Dizziness | 1 | 0 |
| Table 6. Adverse Reactions in a Controlled Clinical Trial in Moderate to Severe Alzheimer’s Disease | ||
| Adverse Reaction | 23 mg/day ARICEPT (n=963) % | 10 mg/day ARICEPT (n=471) % |
| Percent of Patients with any Adverse Reaction | 74 | 64 |
| Nausea | 12 | 3 |
| Vomiting | 9 | 3 |
| Diarrhea | 8 | 5 |
| Anorexia | 5 | 2 |
| Dizziness | 5 | 3 |
| Weight Loss | 5 | 3 |
| Headache | 4 | 3 |
| Insomnia | 3 | 2 |
| Urinary Incontinence | 3 | 1 |
| Asthenia | 2 | 1 |
| Contusion | 2 | 0 |
| Fatigue | 2 | 1 |
| Somnolence | 2 | 1 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no adequate data on the developmental risks associated with the use of ARICEPT in pregnant women. In animal studies, developmental toxicity was not observed when donepezil was administered to pregnant rats and rabbits during organogenesis, but administration to rats during the latter part of pregnancy and throughout lactation resulted in increased stillbirths and decreased offspring survival at clinically relevant doses [see Data].
In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. The background risks of major birth defects and miscarriage for the indicated population are unknown. Data Animal Data Oral administration of donepezil to pregnant rats and rabbits during the period of organogenesis did not produce any teratogenic effects at doses up to 16 mg/kg/day (approximately 6 times the maximum recommended human dose [MRHD] of 23 mg/day on a mg/m 2 basis) and 10 mg/kg/day (approximately 7 times the MRHD on a mg/m 2 basis), respectively.
Oral administration of donepezil (1, 3, 10 mg/kg/day) to rats during late gestation and throughout lactation to weaning produced an increase in stillbirths and reduced offspring survival through postpartum day 4 at the highest dose. The no-effect dose of 3 mg/kg/day is approximately equal to the MRHD on a mg/m 2 basis.
Mechanism of action
12.1 Mechanism of Action Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process.
US FDA labelPharmacokinetics
The elimination half life of donepezil is about 70 hours, and the mean apparent plasma clearance (Cl/F) is 0.13-0.19 L/hr/kg.
Donepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Pharmacokinetics of donepezil are linear over a dose range of 1-10 mg given once daily. The rate and extent of absorption of ARICEPT tablets are not influenced by food. Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for ARICEPT 23 mg tablets in approximately 8 hours, compared with 3 hours for ARICEPT 10 mg tablets.
Peak plasma concentrations were about 2-fold higher for ARICEPT 23 mg tablets than ARICEPT 10 mg tablets. ARICEPT ODT 5 mg and 10 mg are bioequivalent to ARICEPT 5 mg and 10 mg tablets, respectively. A food effect study has not been conducted with ARICEPT ODT; however, the effect of food with ARICEPT ODT is expected to be minimal.
ARICEPT ODT can be taken without regard to meals. The elimination half life of donepezil is about 70 hours, and the mean apparent plasma clearance (Cl/F) is 0.13-0.19 L/hr/kg. Following multiple dose administration, donepezil accumulates in plasma by 4-7 fold, and steady state is reached within 15 days. The steady state volume of distribution is 12-16 L/kg.
Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL. Donepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified.
Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation. Following administration of 14 C-labeled donepezil, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact donepezil (53%) and as 6-O-desmethyl donepezil (11%), which has been reported to inhibit AChE to the same extent as donepezil in vitro and was found in plasma at concentrations equal to about 20% of donepezil.
Approximately 57% and 15% of the total radioactivity was recovered in urine and feces, respectively, over a period of 10 days, while 28% remained unrecovered, with about 17% of the donepezil dose recovered in the urine as unchanged drug. Examination of the effect of CYP2D6 genotype in Alzheimer’s patients showed differences in clearance values among CYP2D6 genotype subgroups.
When compared to the extensive metabolizers, poor metabolizers had a 31.5% slower clearance and ultra-rapid metabolizers had a 24% faster clearance. Hepatic Disease In a study of 10 patients with stable alcoholic cirrhosis, the clearance of ARICEPT was decreased by 20% relative to 10 healthy age- and sex-matched subjects.
Renal Disease In a study of 11 patients with moderate to severe renal impairment (Cl C < 18 mL/min/1.73 m²) the clearance of ARICEPT did not differ from 11 age- and sex-matched healthy subjects. Age No formal pharmacokinetic study was conducted to examine age-related differences in the pharmacokinetics of ARICEPT. Population pharmacokinetic analysis suggested that the clearance of donepezil in patients decreases with increasing age.
When compared with 65-year old subjects, 90-year old subjects have a 17% decrease in clearance, while 40-year old subjects have a 33% increase in clearance. The effect of age on donepezil clearance may not be clinically significant. Gender and Race No specific pharmacokinetic study was conducted to investigate the effects of gender and race on the disposition of ARICEPT.
However, retrospective pharmacokinetic analysis and population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease indicates that gender and race (Japanese and Caucasians) did not affect the clearance of ARICEPT to an important degree. Body W eight There was a relationship noted between body weight and clearance.
Over the range of body weight from 50 kg to 110 kg, clearance increased from 7.77 L/h to 14.04 L/h, with a value of 10 L/hr for 70 kg individuals. Drug Interactions Effect of ARICEPT on the Metabolism of Other Drugs No in vivo clinical trials have investigated the effect of ARICEPT on the clearance of drugs metabolized by CYP 3A4 (e.g., cisapride, terfenadine) or by CYP 2D6 (e.g., imipramine).
However, in vitro studies show a low rate of binding to these enzymes (mean K i about 50-130 μM), that, given the therapeutic plasma concentrations of donepezil (164 nM), indicates little likelihood of interference. Based on in vitro studies, donepezil shows little or no evidence of direct inhibition of CYP2B6, CYP2C8, and CYP2C19 at clinically relevant concentrations.
Whether ARICEPT has any potential for enzyme induction is not known. Formal pharmacokinetic studies evaluated the potential of ARICEPT for interaction with theophylline, cimetidine, warfarin, digoxin, and ketoconazole. No effects of ARICEPT on the pharmacokinetics of these drugs were observed. Effect of Other Drugs on the Metabolism of ARICEPT Ketoconazole and quinidine, strong inhibitors of CYP450 3A and 2D6, respectively, inhibit donepezil metabolism in vitro.
Whether there is a clinical effect of quinidine is not known. Population pharmacokinetic analysis showed that in the presence of concomitant CYP2D6 inhibitors donepezil AUC was increased by approximately 17% to 20% in Alzheimer’s disease patients taking ARICEPT 10 and 23 mg. This represented an average effect of weak, moderate, and strong CYP2D6 inhibitors.
In a 7-day crossover study in 18 healthy volunteers, ketoconazole (200 mg q.d.) increased mean donepezil (5 mg q.d.) concentrations (AUC 0-24 and C max) by 36%. The clinical relevance of this increase in concentration is unknown. Inducers of CYP 3A (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of ARICEPT.
Formal pharmacokinetic studies demonstrated that the metabolism of ARICEPT is not significantly affected by concurrent administration of digoxin or cimetidine. An in vitro study showed that donepezil was not a substrate of P-glycoprotein. Drugs Highly Bound to Plasma Proteins Drug displacement studies have been performed in vitro between this highly bound drug (96%) and other drugs such as furosemide, digoxin, and warfarin.
ARICEPT at concentrations of 0.3-10 micrograms/mL did not affect the binding of furosemide (5 micrograms/mL), digoxin (2 ng/mL), and warfarin (3 micrograms/mL) to human albumin. Similarly, the binding of ARICEPT to human albumin was not affected by furosemide, digoxin, and warfarin.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Donepezil Hydrochloride 5 mg Tablet | ₱8.80–₱14.30Reference ₱9.63 | per tablet | DPRI procurement range |
| Donepezil Hydrochloride 10 mg Tablet | ₱15.50–₱50.00Reference ₱15.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Donepezil |
| PNF listing | Oral: 5 mg and 10 mg tablet/ orodispersible tablet (ODT) |
| PNF listing | 23 mg film-coated tablet (as hydrochloride) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Advisory No. 2025-0013, PNF 8th ed. EML 2019 as of November 2, 2022 with newly approved medicines as of January 27, 2025; DOH-DC No. 2024-0498 (included 2024-11-22); https://www.philhealth.gov.ph/advisories/2025/PA2025-0013.pdf, as of November 22, 2024
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Aricept · Eisai Inc. [US FDA-approved label, version 33, December 30, 2021]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e451e1-e4d7-4439-a675-c5457ba20975
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Advisory No. 2025-0013, PNF 8th ed. EML 2019 as of November 2, 2022 with newly approved medicines as of January 27, 2025; DOH-DC No. 2024-0498 (included 2024-11-22); https://www.philhealth.gov.ph/advisories/2025/PA2025-0013.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .